AbbVie’s Migraine-Prevention Drug Wins FDA Approval

AbbVie’s drug Qulipta (atogepant) has gained FDA approval for preventive treatment of episodic migraine in adults.

The drug is a calcitonin gene-related peptide (CGRP) receptor antagonist — a new focus in migraine drugs.

The first oral CGRP receptor antagonist specifically developed for the indication, Qulipta caused a 50 to 100 percent reduction in monthly migraine days among adult participants with episodic migraines in a phase 3 study.

“This approval reflects a broader shift in the treatment and management paradigm for the migraine community,” said Peter Goadsby, neurologist and principal investigator in the phase 3 study.